Compare FBRT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBRT | ABUS |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | 223 | 19 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 701.9M | 848.8M |
| IPO Year | N/A | 2008 |
| Metric | FBRT | ABUS |
|---|---|---|
| Price | $9.03 | $4.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $11.50 | $5.00 |
| AVG Volume (30 Days) | 708.0K | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 15.83% | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $12.34 | N/A |
| Revenue Next Year | $4.95 | $239.71 |
| P/E Ratio | $13.56 | ★ $4.81 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $8.24 | $3.04 |
| 52 Week High | $11.84 | $5.10 |
| Indicator | FBRT | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 42.04 |
| Support Level | $8.91 | $4.17 |
| Resistance Level | $9.26 | $4.62 |
| Average True Range (ATR) | 0.22 | 0.15 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 39.53 | 23.96 |
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. The Company's operations are organized into two business units: (i) Commercial Real Estate Financing, and (ii) Agency Business. Its four reporting segments are as follows: The real estate debt business, The Agency Business, The commercial real estate conduit business, and The real estate owned business.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.